Frontier Medicines Presents Breakthrough Data on FMC-220, First-in-Class p53 Y220C Activator for Cancer Treatment
• Frontier Medicines unveiled promising preclinical data for FMC-220, a novel covalent activator of mutant p53 Y220C, demonstrating durable anti-tumor activity across multiple cancer models including those with KRAS co-mutations.
• FMC-220 overcomes potency and durability limitations of non-covalent approaches by selectively stabilizing the p53 Y220C protein at lower doses, effectively reactivating its tumor-suppressive functions and triggering cancer cell death pathways.
• The drug candidate addresses approximately 1-2% of cancers with the TP53 Y220C mutation, particularly prevalent in lung, breast, ovarian, and colorectal cancers, with an IND filing planned for the second half of 2025.
© Copyright 2025. All Rights Reserved by MedPath